Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.

Jérôme Bouligand; Odile Cabaret; Marianne Canonico; Céline Verstuyft; Liliane Dubert; Laurent Becquemont; Anne Guiochon-Mantel; Pierre Yves Scarabin

doi:10.1038/clpt.2010.241

Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.

Jérôme Bouligand ^{1, 2} Odile Cabaret ¹ Marianne Canonico ³ Céline Verstuyft ^{1, 4} Liliane Dubert ⁴ Laurent Becquemont ^{1, 4} Anne Guiochon-Mantel ^{1, 2} Pierre Yves Scarabin ³

1 Service de génétique moléculaire, pharmacogénétique et hormonologie

2 Récepteurs stéroïdiens : physiopathologie endocrinienne et métabolique

3 CESP - Centre de recherche en épidémiologie et santé des populations

4 Département de pharmacologie

Abstract : Oral, but not transdermal, estrogen therapy increases the risk of venous thromboembolism (VTE) in women who are past menopause. Data from the Estrogen and Thromboembolism Risk (ESTHER) study were used to investigate the effects of the genetic polymorphism of NFE2L2 rs6721961, which may impair Nrf2-dependent hepatic conjugation of estrogen metabolites. As compared with nonusers, the odds ratio (OR) for VTE in current users of oral estrogens was 2.5 (95% confidence interval (CI): 1.3-4.8) in patients with wild-type NFE2L2 and 17.9 (95% CI: 3.7-85.7) in those with the polymorphism (interaction, P = 0.01).

Keywords : Pharmacogenetics Venous thromboembolism Words count: abstract: 75 words NFE2L2 (Nrf2) Estradiol

Type de document :

Article dans une revue

Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2010, 89 (1), pp.60-4. 〈10.1038/clpt.2010.241〉

Domaine :

Sciences du Vivant [q-bio] / Santé publique et épidémiologie

Liste complète des métadonnées

Littérature citée [24 références] Voir Masquer Télécharger

http://www.hal.inserm.fr/inserm-01142843
Contributeur : Pascale Sztajnbok <>
Soumis le : jeudi 16 avril 2015 - 10:08:31
Dernière modification le : vendredi 17 février 2017 - 14:30:32
Document(s) archivé(s) le : lundi 14 septembre 2015 - 09:36:42

Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.

Fichier

Accès restreint

Identifiants

Collections

Citation

Exporter

Métriques

175

Contact

Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.

Fichier

Accès restreint

Identifiants

Collections

Citation

Exporter

Partager

Métriques

175

Contact